Advertisement

Current Oncology Reports

, 19:58 | Cite as

New Hypofractionation Radiation Strategies for Glioblastoma

  • Melissa Azoulay
  • Jennifer Shah
  • Erqi Pollom
  • Scott G. Soltys
Neuro-oncology (S Nagpal, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neuro-oncology

Abstract

Purpose of Review

Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed GBM.

Recent Findings

Investigators have explored alternative radiotherapy strategies that shorten treatment duration with the goal of similar or improved survival while minimizing toxicity. HFRT over 1–3 weeks is already a standard of care for patients with advanced age or poor performance status. For young patients with good performance status, HFRT holds the promise of radiobiologically escalating the dose and potentially improving local control while maintaining quality of life.

Summary

Through the use of shorter radiotherapy fractionation regimens coupled with novel systemic agents, improved outcomes for patients with GBM may be achieved.

Keywords

Hypofractionation Glioblastoma Stereotactic radiosurgery Radiation Radiotherapy Temozolomide Radionecrosis Adverse radiation effect Immunotherapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Melissa Azoulay declares that she has no conflict of interest.

Jennifer Shah declares that she has no conflict of interest.

Erqi Pollom declares that she has no conflict of interest.

Scott G. Soltys has served on an advisory board for Nektar Therapeutics.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • of Importance •• of major importance

  1. 1.
    Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001. Neurosurg Focus. 2006;20(4):E1.CrossRefPubMedGoogle Scholar
  2. 2.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefPubMedGoogle Scholar
  3. 3.
    •• Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–43. For patients who desire the addition of tumor-treating fields, this prospective trial defines the standard of care CrossRefPubMedGoogle Scholar
  4. 4.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.CrossRefPubMedGoogle Scholar
  5. 5.
    Budach W, Gioioso D, Taghian A, Stuschke M, Suit HD. Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro. Int J Radiat Oncol Biol Phys. 1997;39(3):743–50.CrossRefPubMedGoogle Scholar
  6. 6.
    Hingorani M, Colley WP, Dixit S, Beavis AM. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future? Br J Radiol. 2012;85(1017):e770–81.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998;42(3):581–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Mori Y, Kondziolka D, Flickinger JC, Logan T, Lunsford LD. Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer. 1998;83(2):344–53.CrossRefPubMedGoogle Scholar
  9. 9.
    Ciammella P, Galeandro M, D'Abbiero N, Podgornii A, Pisanello A, Botti A, et al. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience. Clin Neurol Neurosurg. 2013;115(9):1609–14.CrossRefPubMedGoogle Scholar
  10. 10.
    Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, et al. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012;84(3):655–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Floyd NS, Woo SY, Teh BS, Prado C, Mai WY, Trask T, et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004;58(3):721–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, et al. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Radiat Oncol. 2013;8:38.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, et al. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;81(4):1066–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Iuchi T, Hatano K, Kodama T, Sakaida T, Yokoi S, Kawasaki K, et al. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2014;88(4):793–800.CrossRefPubMedGoogle Scholar
  15. 15.
    •• Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(18):3048–53. This retrospective study describes the most commonly used hypofractionated radiotherapy schedule for recurrent GBM CrossRefGoogle Scholar
  16. 16.
    Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, et al. International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33(35):4145–50.CrossRefGoogle Scholar
  17. 17.
    Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–37.Google Scholar
  18. 18.
    •• Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(19):5023–31. A prospective trial which had the promising finding that hypofractionated radiotherapy with bevacizumab may overcome the negative prognostic significance of MGMT hypermethylation.CrossRefGoogle Scholar
  19. 19.
    • Ney DE, Carlson JA, Damek DM, Gaspar LE, Kavanagh BD, Kleinschmidt-DeMasters BK, et al. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. J Neuro-Oncol. 2015;122(1):135–43. The last of the University of Colorado trials of hypofractionated radiotherapy, highlighting the risk of radiation necrosis and need for optimal patient selection. CrossRefGoogle Scholar
  20. 20.
    Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487–95.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333–43.CrossRefPubMedGoogle Scholar
  23. 23.
    Kita M, Okawa T, Tanaka M, Ikeda M. Radiotherapy of malignant glioma–prospective randomized clinical study of whole brain vs local irradiation. Gan No Rinsho. 1989;35(11):1289–94.PubMedGoogle Scholar
  24. 24.
    Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, et al. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys. 2006;65(5):1422–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004;60(3):853–60.CrossRefPubMedGoogle Scholar
  26. 26.
    Mehta MP, Masciopinto J, Rozental J, Levin A, Chappell R, Bastin K, et al. Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys. 1994;30(3):541–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Loeffler JS, Alexander E 3rd, Wen PY, Shea WM, Coleman CN, Kooy HM, et al. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst. 1990;82(24):1918–21.CrossRefPubMedGoogle Scholar
  28. 28.
    Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002;62(15):4307–15.PubMedGoogle Scholar
  29. 29.
    Loeffler JS, Alexander E 3rd, Shea WM, Wen PY, Fine HA, Kooy HM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol: Off J Am Soc Clin Oncol. 1992;10(9):1379–85.CrossRefGoogle Scholar
  30. 30.
    Buatti JM, Friedman WA, Bova FJ, Mendenhall WM. Linac radiosurgery for high-grade gliomas: the University of Florida experience. Int J Radiat Oncol Biol Phys. 1995;32(1):205–10.CrossRefPubMedGoogle Scholar
  31. 31.
    Gannett D, Stea B, Lulu B, Adair T, Verdi C, Hamilton A. Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas. Int J Radiat Oncol Biol Phys. 1995;33(2):461–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Anker CJ, Hymas RV, Hazard LJ, Boucher KM, Jensen RL, Shrieve DC. Stereotactic radiosurgery eligibility and selection bias in the treatment of glioblastoma multiforme. J Neuro-Oncol. 2010;98(2):253–63.CrossRefGoogle Scholar
  33. 33.
    Shenouda G, Souhami L, Freeman CR, Hazel J, Lehnert S, Joseph L. Accelerated fractionation for high-grade cerebral astrocytomas. Preliminary treatment results. Cancer. 1991;67(9):2247–52.CrossRefPubMedGoogle Scholar
  34. 34.
    Sultanem K, Patrocinio H, Lambert C, Corns R, Leblanc R, Parker W, et al. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys. 2004;58(1):247–52.CrossRefPubMedGoogle Scholar
  35. 35.
    Neider CNU, Walter K, Niewald M, Schnabel K. Hypofractionated stereotactic radiotherapy for malignant glioma: a phase I/II study. J Radiosurg. 1999;2(2):107–11.CrossRefGoogle Scholar
  36. 36.
    Hulshof MC, Schimmel EC, Andries Bosch D, Gonzalez Gonzalez D. Hypofractionation in glioblastoma multiforme. Radiother Oncol: J Eur Soc Ther Radiol Oncol. 2000;54(2):143–8.CrossRefGoogle Scholar
  37. 37.
    Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(9):1583–8.CrossRefGoogle Scholar
  38. 38.
    EORTC. Quality of life questionnaire.Google Scholar
  39. 39.
    Shenouda GSL, Petrecca K, Owen S, Panet-Raymond V, Guiot M-C, Gomez Corredor A, et al. A phase II trial of neo-adjuvant temozolomide followed by hypofractionated accelerated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma. International Journal of Radiation Oncology • Biology • Physics. 2016;Google Scholar
  40. 40.
    Azoulay M, Ho CK, Fujimoto D, Modlin LA, Gibbs IC, Hancock SL, et al. A phase I/II trial of 5 fraction stereotactic radiosurgery with 5-mm margins with concurrent and adjuvant temozolomide in newly diagnosed supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2016;96(2:Supplement):E131–E2.CrossRefGoogle Scholar
  41. 41.
    Pollom EL, Fujimoto D, Wynne J, Seiger K, Modlin LA, Jacobs LR, et al. Phase 1/2 trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent and adjuvant temozolomide in newly diagnosed supratentorial glioblastoma: health-related quality of life results. Int J Radiat Oncol Biol Phys. 2017;98(1):123–30.Google Scholar
  42. 42.
    Reddy K, Gaspar LE, Kavanagh BD, Waziri A, Damek DM, Ney D, et al. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. J Neuro-Oncol. 2013;114(1):111–6.CrossRefGoogle Scholar
  43. 43.
    Minniti G, Scaringi C, Baldoni A, Lanzetta G, De Sanctis V, Esposito V, et al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. Int J Radiat Oncol Biol Phys. 2013;86(2):285–91.CrossRefPubMedGoogle Scholar
  44. 44.
    Schwer AL, Damek DM, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, et al. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2008;70(4):993–1001.CrossRefPubMedGoogle Scholar
  45. 45.
    Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Meyer KK. Radiation-induced lymphocyte-immune deficiency. A factor in the increased visceral metastases and decreased hormonal responsiveness of breast cancer. Arch Surg. 1970;101(2):114–21.CrossRefPubMedGoogle Scholar
  47. 47.
    Yovino S, Grossman SA. Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS Oncol. 2012;1(2):149–54.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26.CrossRefPubMedGoogle Scholar
  49. 49.
    Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, et al. Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008–2013. JAMA. 2014;312(23):2542–50.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Muralidhar V, Nguyen PL. Maximizing resources in the local treatment of prostate cancer: a summary of cost-effectiveness studies. Urol Oncol 2016.Google Scholar
  51. 51.
    Morganti AG, Balducci M, Salvati M, Esposito V, Romanelli P, Ferro M, et al. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2010;77(1):92–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Terasaki M, Eto T, Nakashima S, Okada Y, Ogo E, Sugita Y, et al. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. J Neuro-Oncol. 2011;102(2):247–53.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Melissa Azoulay
    • 1
  • Jennifer Shah
    • 2
  • Erqi Pollom
    • 2
  • Scott G. Soltys
    • 2
  1. 1.Department of Radiation OncologyMcGill University Health Centre, Glen siteMontrealCanada
  2. 2.Department of Radiation OncologyStanford University Cancer CenterStanfordUSA

Personalised recommendations